Quick Answer
MiNK Therapeutics, Inc. reported Diluted EPS of $2.93 per share (loss) for fiscal year 2025.
MiNK Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.93 | -2.4% |
| 2024 | -$2.86 | +56.3% |
| 2023 | -$6.54 | -688.0% |
| 2022 | -$0.83 | +28.4% |
| 2021 | -$1.16 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.65 | -41.3% | +38.7% |
| June 30, 2025 | -$1.06 | -45.2% | -51.4% |
| March 31, 2025 | -$0.70 | +36.4% | -52.2% |
| September 30, 2024 | -$0.46 | -206.7% | +37.0% |
| June 30, 2024 | -$0.73 | -305.6% | +33.6% |
| March 31, 2024 | -$1.10 | -547.1% | -633.3% |
| September 30, 2023 | -$0.15 | +21.1% | +16.7% |
| June 30, 2023 | -$0.18 | +0.0% | -5.9% |
- MiNK Therapeutics, Inc. showed a decrease of -2.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, MiNK Therapeutics, Inc.’s diluted eps has declined by 152.6% (from $1.16 per share (loss) to $2.93 per share (loss)).
- The most recent figure is from MiNK Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: